Slide 1: PROPEL 3 Phase 3 Topline Results of Infigratinib in Achondroplasia
PROPEL 3 Phase 3 Topline Results of Infigratinib in Achondroplasia February 12, 2026 BridgeBio 1
Slide 2: Forward looking statements and disclaimers
Forward looking statements and disclaimers TStatements made or presented in this presentation may include statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securit
Slide 3: Agenda
Agenda Neil Kumar, Ph.D. 1 Introduction Chief Executive Officer, BridgeBio Justin To 2 PROPEL 3 Summary Chief Executive Officer, Skeletal Dysplasias PROPEL 3 Phase 3 Daniela Rogoff, M.D., PhD. 3 Topline Results Chief Medical Officer, Skeletal Dysplasias Justin To 4 Program Next Steps Chief Executive
Slide 4: Introduction
Introduction Neil Kumar, Ph.D. Chief Executive Officer, BridgeBio BridgeBio The following properties are intended solely for internal presentation purposes. 4
Slide 5: Infigratinib for Achondroplasia: Thank you to families and advocates
Infigratinib for Achondroplasia A sincere THANK YOU to families, advocates, investigators, clinical research staff, and collaborating research partners 5
Slide 6: We have built a sustainable, high velocity engine to deliver hope and medicines
We have built a sustainable, high velocity engine to deliver hope and medicines to the communities that we serve > 8,500 individuals impacted by our therapies Obtained Approval for 3 Medicines 3 Positive + 1 Ongoing Phase 3 Results Pivotal Trials 15 > 70 > 35 19 < $40M active trials papers aca
Slide 7: We leverage lean operating teams that advance medicines quickly and efficiently
We leverage lean operating teams that advance medicines quickly and efficiently for people living with rare diseases Topline Avg. Team Size BBP-418 IND ~5.5 Years <30 FTEs for LGMD2I Topline IND ~6 Years Encaleret <30 FTEs for ADH1 Topline IND ~6 Years Infigratinib <60 FTEs for Achondroplasia Toplin
Slide 8: We target well-described diseases at their source, underpinning probability of technical success
We target well-described diseases at their source, underpinning our industry-leading probability of technical success Probability of Technical Success (POTS) Approaching engineering-like success • Certain Rare/Genetic Disease sub- Clinical Dev. Industry BBIO categories are particularly likely to suc
Slide 9: We are at day 1 of genetic medicine
We are at day 1 of genetic medicine: Our engine sits on top of an explosion of new science and promising substrate • Larger Biobanks: UKB, • Perturb-seq to perturb every AOU, ADG, etc. Saturation of genetic High throughput single gene across the • WGS for non-coding rare variants affecting perturbat
Slide 10: PROPEL 3 Phase 3 Topline Overview
PROPEL 3 Phase 3 Topline Overview Justin To Chief Executive Officer Skeletal Dysplasias BridgeBio The following properties are intended solely for internal presentation purposes. 10
Slide 11: Infigratinib: Connecting the dots between genetics, nonclinical, and clinical data
Infigratinib: Connecting the dots between genetics, nonclinical, and clinical data to do more for families and individuals living with achondroplasia We are developing the first therapeutic option that directly targets FGFR3 gain-of-function because we believe that we can and should do more and bett
Slide 12: Infigratinib exceeded the bar for a potential best-in-class therapeutic option
Infigratinib exceeded the bar for a potential best-in-class therapeutic option, in the broadest age range studied across any achondroplasia trial Target Clinical Profile for Commercial Outcomes Success CFBL in AHV: More than +1.5 cm/yr against Met the primary endpoint with mean difference against pl
Slide 13: PROPEL 3 Phase 3 Topline Results
PROPEL 3 Phase 3 Topline Results Daniela Rogoff, M.D., Ph.D. Chief Medical Officer Skeletal Dysplasias BridgeBio The following properties are intended solely for internal presentation purposes. 13
Slide 14: PROPEL 3 - Phase 3 Registrational Study Design
PROPEL 3 - Phase 3 Registrational Study Design PROPEL: PROPEL 3: Ph3 randomized, double-blinded PROPEL OLE: Observational run-in pivotal trial (n=114 consented)1 Open-label extension 0.25 mg/kg/day infigratinib (n=74) Observational 0.25 mg/kg/day Children are followed for a 2:1 infigratinib minimum
Slide 15: Demographic and baseline characteristics
Demographic and baseline characteristics Infigratinib Placebo All Participants Baseline demographics (n=74) (n=39) (n=113) Age (yrs), mean (SD) 7.92 (2.7) 7.74 (2.5) 7.86 (2.7) (min, max) (3.7 – 14.4) (3.9 – 14.9) (3.7 – 14.9) Age group, n (%) 3 – <5 10 (13.5) 4 (10.3) 14 (12.4) 5 – <11 50 (67.6) 31
Slide 16: Primary endpoint: Change from baseline to Week 52 in AHV
Primary endpoint: Change from baseline to Week 52 in AHV Infigratinib Placebo (n=74) (n=39) Baseline AHV (cm/yr), Mean (SE) 4.28 (0.16) 4.57 (0.23) Week 52 AHV (cm/yr), Mean (SE) 5.75 (0.15) 3.95 (0.14) CFBL AHV at Week 52, Mean (SE) 1.48 (0.22) -0.62 (0.29) Infigratinib vs. placebo difference, Mean
Slide 17: Subgroup analyses: Change from baseline to Week 52 in AHV by age group
Subgroup analyses: Change from baseline to Week 52 in AHV by age group Age subgroups 3 to < 5 years 5 to < 11 years 11 to < 18 years Infigratinib Placebo Infigratinib Placebo Infigratinib Placebo (n=10) (n=4) (n=50) (n=31) (n=14) (n=4) Infigratinib vs. placebo difference, 2.30 1.93 2.78 Mean Infigra
Slide 18: Secondary endpoint: Absolute AHV at Week 52
Secondary endpoint: Absolute AHV at Week 52 Absolute Annualized Height Velocity (AHV) Average reference AHV 6 Annualized height velocity (average stature) (6 cm/year)2 Infigratinib Placebo Absolute AHV at Week 52 (cm/yr, mean) (n=74) (n=39) 5 LS Mean 5.96 4.22 Infigratinib vs. placebo Average refere
Slide 19: Key secondary endpoint: Change from baseline in height Z-score
Key secondary endpoint: Change from baseline in height Z-score in relation to an achondroplasia population over 52 weeks Change from baseline (CFBL) in ACH height Z-score 0.4 Infigratinib CFBL in ACH height Z-score Placebo ACH Height Z-score at Infigratinib Placebo 0.3 Week 52 (n=74) (n=39) LS Mean
Slide 20: Key secondary endpoint: Change in upper-to-lower body segment ratio
Key secondary endpoint: Change from baseline to Week 52 in upper-to- lower body segment ratio Change from baseline in upper to lower body segment ratio (UL:LL) at Week 52 All ages 3 to < 8 years Infigratinib (n=74) Placebo (n=39) Infigratinib (n=43) Placebo (n=23) 0.00 UL:LL (Change from Baseline) L
Slide 21: Infigratinib at 0.25 mg/kg was well-tolerated
Infigratinib at 0.25 mg/kg was well-tolerated, with no safety signal indicating inhibition of FGFR1 or 2 The majority of treatment-emergent adverse events (TEAEs) were grade 1 or 2 in severity and typical for children of these ages TEAEs were balanced between the treatment and placebo arms No
Slide 22: Mean serum phosphate levels comparable across infigratinib and placebo
Mean serum phosphate levels were comparable across infigratinib and placebo at all measured time points Mean Serum Phosphate Levels Mean serum phosphate levels 7 Infigratinib Placebo 6 Mean serum phosphate levels For all participants, the (mg/dL) maximal change in + SD (mg/dL) 5 phosphate levels was
Slide 23: NDA and MAA submissions expected in 2H 2026
NDA and MAA submissions expected in 2H 2026 Advance infigratinib towards registration in achondroplasia Submit New Drug Application to FDA 2H 2026 Submit Marketing Authorization Application to EMA 2H 2026 Detailed PROPEL 3 results planned for presentation at scientific and advocacy conferences 2026
Slide 24: Infigratinib for Achondroplasia: Thank you to study participants
“Taken together, these best-in-class results highlight Infigratinib for Achondroplasia the transformative potential for infigratinib to address aspects of achondroplasia beyond linear height, and with a product administered orally.” THANK YOU to the study Ravi Savarirayan, M.D., Ph.D. of Murdoch Chi
Slide 25: Program Next Steps
Program Next Steps Justin To Chief Executive Officer Skeletal Dysplasias BridgeBio Subject The following properties are intended solely for internal presentation purposes. 25
Slide 26: We should continue to do more and do better for families with ACH
We should continue to do more and do better for families and individuals with ACH; Today is just the beginning PROPEL OLE will follow children on infigratinib (0.25mg/kg) until Our commitment to the community they reach final or near-final adult height continues Longer Term Objectives: Changes over
Slide 27: We are on Day 1 of the opportunity for infigratinib
We are on Day 1 of the opportunity for infigratinib Achondroplasia (0-3) sNDA-enabling trial, FPI achieved Now enrolling Hypochondroplasia Genotype-driven Accelerating development, (FGFR3 gain-of-function) Now enrolling run-in for Ph. 3 Achondroplasia (Adults) Exploring unique opportunity to potenti
Slide 28: Launch Readiness
Launch Readiness Matt Outten, M.B.A. Chief Commercial Officer BridgeBio BridgeBio The following properties are intended solely for internal presentation purposes. 28
Slide 29: Leveraging our proven commercial structure to successfully launch infigratinib
Leveraging our proven commercial structure to successfully launch infigratinib Built on the foundation of Attruby’s commercial success and tailored to the achondroplasia market opportunity Established commercial infrastructure and Proven competitive launch playbook Ensuring broad access team with tr
Slide 30: Large concentrated market with global $5Bn opportunity
Large concentrated market with global $5Bn opportunity State of the market Addressable market in the U.S. U.S. Prescriber base We are preparing for a global launch People living with achondroplasia Infrastructure and capabilities in place predominantly managed by geneticists to support a global laun
Slide 31: Combining compelling data with a proven commercial platform
Combining compelling data with a proven commercial platform Key highlights Best-in-class efficacy with largest AHV, height-z score Well-tolerated option, with no First- and only oral therapeutic option World-class commercial team and only statistically SAEs related to study drug or providing freedom
Slide 32: Q&A Session
Q&A Session BridgeBio Subject The following properties are intended solely for internal presentation purposes. 32